Key topics include results from the Phase 3 trial of Libtayo for high-risk cutaneous squamous cell carcinoma and data on linvoseltamab for relapsed or refractory multiple myeloma. Other research ...

While you watched DeChambeau golf, you might have wondered something about the logo on his shirt and hat. After all, it doesn't appear to be in line with the sponsors and apparel many of the other ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Compared to the year-ago quarter, this number represents a +29.2% change. Revenues- Libtayo- US: $192.50 million versus the three-analyst average estimate of $214.99 million. The reported number ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

One of them features an admittedly blurry look at Kara’s “S” logo. Back in January, Gunn commemorated the start of Supergirl production by sharing an official behind-the-scenes photo of ...

The average prediction of analysts places 'Revenues- Libtayo- ROW' at $127.95 million. The estimate indicates a change of +22.2% from the prior-year quarter.

Although I do believe the oncology portfolio still needs a few years to mature, this segment is approaching an inflection point, as Libtayo continues to report growth and the company’s ...

But the Games Independent Infrastructure and Coordination Authority does have at least one piece of public-facing progress to show for its work – a new corporate logo for the planned Brisbane ...

Oncology Programs The Company submitted an sBLA to the FDA and a regulatory application in the EU for Libtayo (cemiplimab) in adjuvant CSCC based upon data from a Phase 3 trial which demonstrated ...